Genetic Technologies Return on Tangible Equity 2010-2022 | GENE
Current and historical return on tangible equity values for Genetic Technologies (GENE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Genetic Technologies Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.028B |
$0.005B |
|
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|
